Viatris Stock Today
| VTRS Stock | USD 13.09 0.13 0.98% |
Performance6 of 100
| Odds Of DistressOver 53
|
Viatris is selling for under 13.09 as of the 30th of November 2024; that is 0.98 percent decrease since the beginning of the trading day. The stock's lowest day price was 13.09. Viatris has 53 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Note, on June 29, 2021, Representative Debbie Dingell of US Congress acquired under $15k worth of Viatris's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2020 | Category Healthcare | Classification Health Care |
The company operates in four segments Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Viatris operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 1.19 B outstanding shares of which 20.71 M shares are at this time shorted by private and institutional investors with about 3.07 trading days to cover. More on Viatris
Moving together with Viatris Stock
Moving against Viatris Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Viatris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Scott Smith | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP 500 Index, NASDAQ Composite, ARCA Pharmaceutical, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsViatris can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viatris' financial leverage. It provides some insight into what part of Viatris' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Viatris (VTRS) is traded on NASDAQ Exchange in USA. It is located in 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 and employs 32,000 people. Viatris is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 15.78 B. Viatris conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.19 B outstanding shares of which 20.71 M shares are at this time shorted by private and institutional investors with about 3.07 trading days to cover.
Viatris currently holds about 741.9 M in cash with 2.8 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Viatris Probability Of Bankruptcy
Ownership AllocationViatris shows a total of 1.19 Billion outstanding shares. The majority of Viatris outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viatris to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viatris. Please pay attention to any change in the institutional holdings of Viatris as this could imply that something significant has changed or is about to change at the company. On June 29, 2021, Representative Debbie Dingell of US Congress acquired under $15k worth of Viatris's common stock.
Check Viatris Ownership Details
Viatris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Rubric Capital Management Lp | 2024-06-30 | 20.1 M | |
| Camber Capital Management Llc | 2024-09-30 | 15 M | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 14.1 M | |
| Norges Bank | 2024-06-30 | 12.6 M | |
| Australiansuper Pty Ltd | 2024-09-30 | 12.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 11.6 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 11.5 M | |
| Legal & General Group Plc | 2024-06-30 | 11.4 M | |
| Northern Trust Corp | 2024-09-30 | 10.8 M | |
| Vanguard Group Inc | 2024-09-30 | 141 M | |
| Blackrock Inc | 2024-06-30 | 92.7 M |
Viatris Historical Income Statement
Viatris Stock Against Markets
Viatris Corporate Management
| Melissa Trombetta | Head Relations | Profile | |
| Andrew Enrietti | Chief Officer | Profile | |
| Theodora Mistras | Chief Officer | Profile | |
| David Bayles | Chief Officer | Profile | |
| Sanjeev Sethi | Chief Officer | Profile | |
| Ramkumar Rayapureddy | Chief Officer | Profile |
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.